7.575

3.82% -0.275

Iteos Therapeutics Inc (ITOS)

Overview News Price History Option Chain Financials Discussions Forecast

Iteos Therapeutics Inc stock is traded at $7.575, with a volume of 146.88K. It is down -3.82% in the last 24 hours and down -17.03% over the past month. ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

Previous Close:

$7.85

Open:

$7.8

24h Volume:

146.88K

Relative Volume:

0.22

Market Cap:

$293.73M

Revenue:

$127.70M

Net Income/Loss:

$-108.14M

P/E Ratio:

-9.2378

EPS:

-0.82

Net Cash Flow:

$-117.52M

1W Performance:

-10.76%

1M Performance:

-17.03%

6M Performance:

-58.13%

1Y Performance:

-22.64%

1-Day Range:

$7.54

$7.92

1-Week Range:

$7.54

$8.58

52-Week Range:

$7.54

$18.75

Iteos Therapeutics Inc Stock (ITOS) Company Profile

Name

Iteos Therapeutics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

857-204-4583

Address

321 ARSENAL STREET, WATERTOWN

Employee

157

Twitter

Next Earnings Date

2024-11-05

Latest SEC Filings

ITOS's Discussions on Twitter

Compare ITOS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ITOS	7.55	293.73M	127.70M	-108.14M	-117.52M	-0.82
VRTX	446.39	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	740.49	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.15	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.56	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.47	24.49B	3.30B	-501.07M	1.03B	11.54

Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-05-21	Initiated	H.C. Wainwright	Buy
Oct-08-20	Initiated	Robert W. Baird	Outperform
Aug-18-20	Initiated	JP Morgan	Overweight
Aug-18-20	Initiated	Piper Sandler	Overweight
Aug-18-20	Initiated	SVB Leerink	Outperform
Aug-18-20	Initiated	Wedbush	Outperform

View All

Iteos Therapeutics Inc Stock (ITOS) Latest News

Nov 19, 2024

Insider Buying: Matthew Gall Acquires 5,000 Shares of ITeos Ther - GuruFocus.com

Nov 19, 2024

iTeos Therapeutics CFO Matthew Gall acquires $38,635 in common stock By Investing.com - Investing.com UK

Nov 19, 2024

iTeos Therapeutics’ (ITOS) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 19, 2024

Nov 16, 2024

Equities Analysts Offer Predictions for ITOS FY2024 Earnings - Defense World

Nov 16, 2024

US Bancorp DE Has $123,000 Stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World

Nov 16, 2024

Nov 15, 2024

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year - Simply Wall St

Nov 15, 2024

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year - Yahoo Finance

Nov 15, 2024

HC Wainwright Reaffirms Buy Rating for iTeos Therapeutics (NASDAQ:ITOS) - MarketBeat

Nov 15, 2024

Wedbush Reaffirms Outperform Rating for iTeos Therapeutics (NASDAQ:ITOS) - Defense World

Nov 14, 2024

Nov 13, 2024

iTeos Therapeutics Reports Q3 2024 Financial Results - TipRanks

Nov 13, 2024

iTeos verkündet Finanzergebnisse für das dritte Quartal 2024 und gibt aktuelle Geschäftsinformationen bekannt - GlobeNewswire Inc.

Nov 13, 2024

Nov 12, 2024

Creative Planning Acquires 1,196 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World

Nov 12, 2024

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire

Nov 12, 2024

iTeos Reports Wider Q3 Loss, Maintains $684M Cash Runway Through 2027 | ITOS Stock News - StockTitan

Nov 12, 2024